CARDIOVASCULAR GENOMIC MEDICINE
Prospects for Personalized Cardiovascular Medicine
The Impact of Genomics
Geoffrey S. Ginsburg, MD, PhD, FACC*, , ,*,
Mark P. Donahue, MD, MHS*, and
L. Kristin Newby, MD, MHS, FACC*,
* Division of Cardiovascular Medicine, Department of Medicine
Duke Clinical Research Institute
Center for Genomic Medicine, Institute for Genome Sciences & Policy, Duke University, Durham, North Carolina
Manuscript received April 18, 2005;
revised manuscript received June 23, 2005,
accepted June 30, 2005.
* Reprint requests and correspondence: Dr. Geoffrey S. Ginsburg, Center for Genomic Medicine, Institute for Genome Sciences & Policy, CIEMAS, 101 Science Drive, Box 3382, Durham, North Carolina 27708 (Email: geoffrey.ginsburg{at}duke.edu).
Sequencing of the human genome has ushered in prospects for individualizing cardiovascular health care. There is growing evidence that the practice of cardiovascular medicine might soon have a new toolbox to predict and treat disease more effectively. The Human Genome Project has spawned several important "omic" technologies that allow "whole genome" interrogation of sequence variation (re-sequencing, genotyping, comparative genome hybridization), transcription (expression profiling, tissue arrays), proteins (gas or liquid chromatography and tandem mass spectroscopy [MS]), and metabolites (MS or nuclear magnetic resonance profiling); deoxyribonucleic acid, ribonucleic acid, protein, and metabolic approaches all provide more exacting detail of cardiovascular disease mechanisms and, in some cases, are redefining its taxonomy. Pharmacogenomic approaches are emerging across broad classes of cardiovascular therapeutics to assist practitioners in making more precise decisions about which drugs to give to which patients to optimize the benefit-to-risk ratio. Molecular imaging is developing chemical and biological probes that can sense molecular pathway mechanisms that will allow us to monitor health and disease. Together, these tools will enable a paradigm shift from genetic medicine—on the basis of the study of individual inherited characteristics, most often single genes—to genomic medicine, which by its nature is comprehensive and focuses on the functions and interactions of multiple genes and gene products, among themselves and with their environment. The information gained from such analyses, in combination with clinical data, is now allowing us to assess individual risks and guide clinical management and decision-making, all of which form the basis for cardiovascular genomic medicine.
|
Abbreviations and Acronyms
| | ACE = angiotensin-converting enzyme | | ACS = acute coronary syndromes | | BNP = brain natriuretic peptide | | CAD = coronary artery disease | | CI = confidence interval | | CK = creatine kinase | | CVD = cardiovascular disease | | FLAP = 5-lipoxygenase accessory protein | | hs-CRP = high-sensitivity C-reactive protein | | LQT = long QT | | MEF2A = member of the myocyte enhancer factor 2 transcription factor family | | MI = myocardial infarction | | MS = mass spectroscopy | | NMR = nuclear magnetic resonance | | PUFA = polyunsaturated fatty acid | | RR = relative risk | | SNP = single nucleotide polymorphism |
|
This article has been cited by other articles:
|
|
|
|
 
S. A. Halim, L. K. Newby, and E. M. Ohman
Biomarkers in Cardiovascular Clinical Trials: Past, Present, Future
Clin. Chem.,
January 1, 2012;
58(1):
45 - 53.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
I. Y. Chen and J. C. Wu
Cardiovascular Molecular Imaging: Focus on Clinical Translation
Circulation,
February 1, 2011;
123(4):
425 - 443.
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. E. Baird
Genetics and Genomics of Stroke: Novel Approaches
J. Am. Coll. Cardiol.,
July 20, 2010;
56(4):
245 - 253.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. M. Califf, S. H. Shah, and L. K. Newby
Biomarker Bonanza?
J. Am. Coll. Cardiol.,
March 23, 2010;
55(12):
1197 - 1199.
[Full Text]
[PDF]
|
|
|
|
|
|
|
American College of Cardiology Foundation, American Heart Association, American College of Physicians Task Force on Compe, American Academy of Neurology, American Association of Cardiovascular and Pulmona, American College of Preventive Medicine, American Diabetes Association, American Society of Hypertension, Association of Black Cardiologists, National Lipid Association, et al.
ACCF/AHA/ACP 2009 Competence and Training Statement: A Curriculum on Prevention of Cardiovascular Disease
J. Am. Coll. Cardiol.,
September 29, 2009;
54(14):
1336 - 1363.
[Full Text]
[PDF]
|
|
|
|
|
|
|
WRITING COMMITTEE MEMBERS, C. N. Bairey Merz, M. J. Alberts, G. J. Balady, C. M. Ballantyne, K. Berra, H. R. Black, R. S. Blumenthal, M. H. Davidson, S. B. Fazio, et al.
ACCF/AHA/ACP 2009 Competence and Training Statement: A Curriculum on Prevention of Cardiovascular Disease: A Report of the American College of Cardiology Foundation/American Heart Association/American College of Physicians Task Force on Competence and Training (Writing Committee to Develop a Competence and Training Statement on Prevention of Cardiovascular Disease): Developed in Collaboration With the American Academy of Neurology; American Association of Cardiovascular and Pulmonary Rehabilitation; American College of Preventive Medicine; American College of Sports Medicine; American Diabetes Association; American Society of Hypertension; Association of Black Cardiologists; Centers for Disease Control and Prevention; National Heart, Lung, and Blood Institute; National Lipid Association; and Preventive Cardiovascular Nurses Association
Circulation,
September 29, 2009;
120(13):
e100 - e126.
[Full Text]
[PDF]
|
|
|
|
|
|
|
G. S. Ginsburg, S. H. Shah, and J. J. McCarthy
Taking Cardiovascular Genetic Association Studies to the Next Level
J. Am. Coll. Cardiol.,
September 4, 2007;
50(10):
930 - 932.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
F. A. Jaffer, P. Libby, and R. Weissleder
Molecular Imaging of Cardiovascular Disease
Circulation,
August 28, 2007;
116(9):
1052 - 1061.
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. Tegner, J. Skogsberg, and J. Bjorkegren
Thematic review series: Systems Biology Approaches to Metabolic and Cardiovascular Disorders. Multi-organ whole-genome measurements and reverse engineering to uncover gene networks underlying complex traits
J. Lipid Res.,
February 1, 2007;
48(2):
267 - 277.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. N. DeMaria, O. Ben-Yehuda, G. K. Feld, G. S. Ginsburg, B. H. Greenberg, W. Y.W. Lew, J. A.C. Lima, A. S. Maisel, J. Narula, D. J. Sahn, et al.
Highlights of the Year in JACC 2006
J. Am. Coll. Cardiol.,
January 30, 2007;
49(4):
509 - 527.
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. Anwaruddin, A. T. Askari, and E. J. Topol
Redefining Risk in Acute Coronary Syndromes Using Molecular Medicine
J. Am. Coll. Cardiol.,
January 23, 2007;
49(3):
279 - 289.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
G. J. Hankey
Potential New Risk Factors for Ischemic Stroke: What Is Their Potential?
Stroke,
August 1, 2006;
37(8):
2181 - 2188.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
P. Kohli and P. Greenland
Role of the Metabolic Syndrome in Risk Assessment for Coronary Heart Disease
JAMA,
February 15, 2006;
295(7):
819 - 821.
[Full Text]
[PDF]
|
|
|
|
